001     127364
005     20240228140922.0
024 7 _ |a 10.1172/JCI74894
|2 doi
024 7 _ |a pmid:25562322
|2 pmid
024 7 _ |a pmc:PMC4319435
|2 pmc
024 7 _ |a 0021-9738
|2 ISSN
024 7 _ |a 1558-8238
|2 ISSN
024 7 _ |a altmetric:3007767
|2 altmetric
037 _ _ |a DKFZ-2017-03389
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Reissfelder, Christoph
|b 0
245 _ _ |a Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.
260 _ _ |a Ann Arbor, Mich.
|c 2015
|b ASCJ
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521638859_922
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The composition of tumor-targeted T cell infiltrates is a major prognostic factor in colorectal cancer (CRC) outcome; however, the functional role of these populations in prolonging patient survival remains unclear. Here, we evaluated 190 patients with CRC for the presence of functionally active tumor-infiltrating lymphocytes (TILs), the tumor specificity of these TILs, and the correlation between patient TILs and long-term survival. Using intracytoplasmic cytokine staining in conjunction with HLA multimers loaded with tumor peptide and antigen-specific cytokine secretion assays, we determined that TNF-α expression delineates a population of tumor antigen-specific (TA-specific) cytotoxic T lymphocytes (CTLs) present within tumors from patients with CRC. Upregulation of TNF-α expression in TILs strongly correlated with an increase in the total amount of intratumoral TNF-α, which is indicative of tumor-specific CTL activity. Moreover, a retrospective multivariate analysis of 102 patients with CRC, which had multiple immune parameters evaluated, revealed that increased TNF-α concentration was an independent prognostic factor. Together, these results indicate that the prognostic impact of T cell infiltrates for CRC maybe largely based on subpopulations of active TA-specific T cells within the tumor, suggesting causal implication for these cells in patient survival. Additionally, these results support the use of intratumoral TNF-α, which is indicative of T cell function, as a prognostic parameter for CRC.
536 _ _ |a 314 - Tumor immunology (POF3-314)
|0 G:(DE-HGF)POF3-314
|c POF3-314
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Neoplasm Proteins
|2 NLM Chemicals
650 _ 7 |a TNF protein, human
|2 NLM Chemicals
650 _ 7 |a Tumor Necrosis Factor-alpha
|2 NLM Chemicals
700 1 _ |a Stamova, Slava
|b 1
700 1 _ |a Gossmann, Christina
|b 2
700 1 _ |a Braun, Marion
|b 3
700 1 _ |a Bonertz, Andreas
|b 4
700 1 _ |a Walliczek, Ute
|b 5
700 1 _ |a Grimm, Mario
|b 6
700 1 _ |a Rahbari, Nuh N
|b 7
700 1 _ |a Koch, Moritz
|b 8
700 1 _ |a Saadati, Maral
|0 P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74
|b 9
|u dkfz
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 10
|u dkfz
700 1 _ |a Büchler, Markus W
|b 11
700 1 _ |a Jäger, Dirk
|b 12
700 1 _ |a Halama, Niels
|b 13
700 1 _ |a Khazaie, Khashayarsha
|b 14
700 1 _ |a Weitz, Jürgen
|b 15
700 1 _ |a Beckhove, Philipp
|0 P:(DE-He78)1732377f6242a18280bc6aaa196988d1
|b 16
|e Last author
|u dkfz
773 _ _ |a 10.1172/JCI74894
|g Vol. 125, no. 2, p. 739 - 751
|0 PERI:(DE-600)2018375-6
|n 2
|p 739 - 751
|t The @journal of clinical investigation
|v 125
|y 2015
|x 0021-9738
909 C O |o oai:inrepo02.dkfz.de:127364
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)1732377f6242a18280bc6aaa196988d1
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-314
|2 G:(DE-HGF)POF3-300
|v Tumor immunology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN INVEST : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J CLIN INVEST : 2015
920 1 _ |0 I:(DE-He78)D015-20160331
|k D015
|l Translationale Immunologie
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D015-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21